Company intelligence / Profile preview

Cardiol Therapeutics Inc.

Oakville, Ontario, Canadaorpha.net ↗

Ownership: Public · CRDL
Employees: ~18
Development stage: Phase 2

Overview

Cardiol Therapeutics has shown positive Phase II data for CardiolRx in recurrent pericarditis, demonstrating marked reductions in pain, inflammation, and recurrence episodes. The company has advanced to Phase III MAVERIC trial for recurrent pericarditis and completed enrollment in Phase II ARCHER trial for acute myocarditis with topline data expected in Q2 2025. CardiolRx has received FDA Orphan Drug Designation for pericarditis treatment.

Therapeutic areas: Cardiovascular
Modalities: Small moleculesCannabidiol oral solutionSubcutaneous drug formulation
Industry: Biotech

Drug pipeline

1 asset

CRD-38

Preclinical

Partnerships

Meros

Financials

Market cap: $263.4M
Total revenue: $0
Enterprise value: $237.4M

Beyond the preview

Go deeper on Cardiol Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiol Therapeutics Inc..

Explore the full profile